Carol Fabian, MD

Program Leader, Cancer Prevention and Survivorship Research Program
Director, Breast Cancer Prevention Center
Director, Breast Cancer Survivorship Center
Kansas Masonic Research Endowed Chair
cfabian@kumc.edu

Carol Fabian, MD is an internationally and nationally recognized leader in risk assessment and prevention trials for breast cancer. She is a board certified medical oncologist, has 30 years of experience in conducting breast cancer research, and has had continuous funding from the National Cancer Institute for performance of clinical research trials for over 20 years.  She Leads the Cancer Prevention and Survivorship Research Program. She is the Principle Investigator for a number of ongoing prevention trials in breast cancer funded by the National Cancer Institute, including: letrozole for postmenopausal women taking hormone replacement therapy; a diet and exercise trial for postmenopausal overweight women; and a flaxseed derivative trial for pre-menopausal women.

Background

Dr. Fabian received her BA and MD form the University of Kansas and joined the faculty as an Assistant Professor at the University of Kansas Medical Center after completing an Oncology fellowship in 1977. She was appointed Professor in 1987. Dr. Fabian has previously served as the Medical Director of the Clinical Outpatient Cancer Center and currently serves as the Director of the Breast Cancer Prevention Center and the Breast Cancer Survivorship Center, both of which she founded.  She was awarded the Kansas Masonic Endowed Research Chair in 2004. She has received numerous lay and academic awards for her achievements and has served on numerous scientific advisory boards for the National Cancer Institute, and the Susan G. Komen Foundation. She has served on ASCO and AACR scientific program committees  and serves as a reviewer and editorial board member for numerous scientific publications, including: The Journal of the National Cancer Institute, Cancer Epidemiology Biomarkers and Prevention, and Journal of Clinical Oncology. She teaches the module on Breast Cancer Risk Assessment and Prevention Annually at the School of Breast Oncology and authored the module on breast cancer risk assessment and prevention for the American Society of Clinical Oncology.  This was released in 2007 as a prevention teaching tool.

Membership Organizations

• American Association for Cancer Research
• American Society of Breast Disease
• American Society of Clinical Oncology
• American Society of Preventive Oncology
• International Society of Preventive Oncology
• Women in Cancer Research

Recent Publications

1. Tawfik O, Kimler BF, Davis M, Stasik C, Lai SM, Mayo MS, Fan F, Donahue JK, Damjanov I, Thomas P, Connor C, Jewell WR, Smith H, Fabian CJ. Grading invasive ductal carcinoma of the breast: advantages of using automated proliferation index instead of mitotic count.  Virchows Arch 450:627-36,2007. 
2. Bartels PH, Fabian CJ, Kimler BF, Ranger-Moore JR, Frank DH, Yozwiak ML, Alberts DS.  Karyometry of breast epithelial cells acquired by random periareolar fine needle aspiration in women at high risk for breast cancer.  Anal Quant Cytol Histol 29:63-70, 2007.
3. Goldenberg VK, Seewaldt VL, Scott V, Bean GR, Broadwater G, Fabian C, Kimler B, Zalles C, Lipkus IM.  Atypia in random periareolar fine-needle aspiration affects the decision of women at high risk to take tamoxifen for breast cancer chemoprevention.  Cancer Epidemiol Biomarkers Prev 16:1032-4, 2007.
4. Khan QJ, Kimler BF, O'dea AP, Zalles CM, Sharma P, Fabian CJ: Mammographic density does not correlate with Ki-67 expression or cytomorphology in benign breast cells obtained by random periareolar fine needle aspiration from women at high risk for breast cancer. Breast Cancer Res 9:R35, 2007.
5. Fabian CJ, Kimler BF: Use of biomarkers for breast cancer risk assessment and prevention. J Steroid Biochem Mol Biol 106:31-9, 2007.
6. Fabian CJ.   Is there a future for ductal lavage?  Clin Cancer Res 13:4655-6, 2007.
7. Fabian CJ.  Low dose tamoxifen for combination hormone replacement therapy users. J Clin Oncol 25:4162-4164, 2007.
8. Fabian CJ: The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer.  Int J Clin Pract 61:2051-2063, 2007.
9. Fabian C J Tamoxifen or Raloxifene in Postmenopausal Women for Prevention of Breast Cancer: A tale of Two Choices---Counterpoint Cancer Epi demiol Biomarkers Prev 16:2210-2212, 2007
10. Fabian CJ Organ-Specific Cancer Control Breast Cancer in ASCO Curriculum; Cancer Prevention; American Society of Clinical Oncology:  Alexandria Virginia, 2007.